Lenalidomide is active for extramedullary disease in refractory multiple myeloma

被引：14
|
作者：
Nakazato, Tomonori [1 ]
Mihara, Ai [1 ]
Ito, Chisako [1 ]
Sanada, Yukinari [1 ]
Aisa, Yoshinobu [1 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Hematol, Hodogaya Ku, Yokohama, Kanagawa 2408555, Japan
来源：
ANNALS OF HEMATOLOGY | 2012年 / 91卷 / 03期
关键词：
THALIDOMIDE; BORTEZOMIB;
D O I：
10.1007/s00277-011-1272-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：473 / 474
页数：2
相关论文
共 50 条
  • [41] Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo, Antonio
    Dimopoulos, Meletios
    San Miguel, Jesus
    Harousseau, Jean-Luc
    Attal, Michel
    Hussein, Mohamad
    Knop, Stefan
    Ludwig, Heinz
    von Lilienfeld-Toal, Marie
    Sonneveld, Pieter
    BLOOD REVIEWS, 2009, 23 (02) : 87 - 93
  • [42] How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
    de Arriba de la Fuente, Felipe
    Montes Gaisan, Carmen
    de la Rubia Comos, Javier
    CANCERS, 2023, 15 (01)
  • [43] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [44] EXPERIENCE IN THE USE OF LENALIDOMIDE FOR THE TREATMENT OF RELAPSE/REFRACTORY MULTIPLE MYELOMA
    Escobar Cristian, Escolano
    de Marcos Nieves, Somolinos
    Compan Francis, Ona
    Parra Laurentino, Benito
    Zabala Itziar, Carmona
    Gullon Esther, Chica
    Alonso Luis, Garcia
    Monteserin Carmen, Monteserin
    Esteban Teresa, Palomo
    Esteban Casimira, Teno
    Bermejo Ana, Yeguas
    Miguel Angel, Alvarez Juarez
    HAEMATOLOGICA, 2016, 101 : 103 - 103
  • [45] Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ferrara, Katia
    Pane, Fabrizio
    Catalano, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Lenalidomide Is Effective for the Treatment of Bortezomib-Resistant Extramedullary Disease in Patients With Multiple Myeloma: Report of 2 Cases
    Ito, Chisako
    Aisa, Yoshinobu
    Mihara, Ai
    Nakazato, Tomonori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (01): : 83 - 85
  • [47] Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    Ja Min Byun
    Chang-Ki Min
    Kihyun Kim
    Soo-Mee Bang
    Je-Jung Lee
    Jin Seok Kim
    Sung-Soo Yoon
    Youngil Koh
    Journal of Hematology & Oncology, 15
  • [48] Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    Byun, Ja Min
    Min, Chang-Ki
    Kim, Kihyun
    Bang, Soo-Mee
    Lee, Je-Jung
    Kim, Jin Seok
    Yoon, Sung-Soo
    Koh, Youngil
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [49] Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
    Abdallah, Al-Ola
    Mohyuddin, Ghulam Rehman
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Shune, Leyla
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Ganguly, Siddhartha
    Atrash, Shebli
    EJHAEM, 2021, 2 (04): : 757 - 764
  • [50] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
    Manola Zago
    Katharina Oehrlein
    Corinna Rendl
    Corinna Hahn-Ast
    Lothar Kanz
    Katja Weisel
    Annals of Hematology, 2014, 93 : 1993 - 1999
12345